According to a recent market study published by Growth Market Reports, titled, “Global Paroxysmal Atrial Fibrillation Treatment Market by Treatment Type, By Technology, By End-user, and By Region: Size, Share, Trends and Opportunity Analysis, 2015-2030”, the market was valued at US$ 4,822.5 Million in 2021 and is anticipated to expand at a growth rate of 8.8% by 2030.

Paroxysmal atrial fibrillation (PAF) refers to a type of atrial fibrillation (AF) that comes and goes simultaneously. The treatment of PAF aims to manage irregular heart rhythms, control symptoms, and reduce the risk of complications. The treatment comprises minimally invasive procedures such as catheter ablation, electric cardioversion, maze surgery, and others. Catheter ablation is a minimally invasive procedure that involves the insertion of a catheter through a peripheral blood vessel in the heart. This procedure uses radiofrequency and cryotherapy to cause damage to the cells causing atrial fibrillation.

Get Sample Report @ https://growthmarketreports.com/request-sample/5458

The global Paroxysmal Atrial Fibrillation Treatment market has been segmented in terms of treatment type, technology, end-user, and region. In terms of treatment type, the global Paroxysmal Atrial Fibrillation Treatment market is split into pharmacological treatment, non-pharmacological treatment, maze surgery, and electric cardioversion. Based on technology, the market is divided into radiofrequency, laser, cryotherapy, and others. On the basis of end-user, the market is fragmented into hospitals, specialty clinics, and others. Considering regions, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The unexpected advent of the coronavirus pandemic boosted the market. The long-term consequences of the pandemic are difficult to predict, as the world economy is grappling with this crisis, which is expected to have an influence on global trade and the supply chain. Demand for the treatment of paroxysmal atrial fibrillation was high during the COVID-19 period. During the pandemic, atrial fibrillation was prevalent in COVID-19-infected patients in 19% to 21% of the cases. The underlying cause of this disease in COVID-19 patients is still unknown. During the pandemic, the paroxysmal atrial fibrillation treatment market was unaffected and registered positive growth.

Key Takeaways from the Study

  • Players in the global Paroxysmal Atrial Fibrillation Treatment market include ATRICURE, INC., Abbott, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CardioFocus, Johnson & Johnson Services, Inc., Medtronic, Rising Pharma Holdings, Inc., Sanofi, and Siemens Medical Solutions USA, Inc. These players held a major share of the global Paroxysmal Atrial Fibrillation Treatment market in 2021.

  • Increasing prevalence of paroxysmal atrial fibrillation in elderly patients, rising prevalence of strokes, heart failure, and growing preference towards catheter ablation treatment across the globe are key factors that drive the Paroxysmal Atrial Fibrillation Treatment market.

  • Government initiatives and better disease management is expected to create opportunities in the coming years.

  • Based on treatment type, the market is segmented into pharmacological treatment, non-pharmacological treatment, maze surgery, and electric cardioversion. The pharmacological treatment segment is expected to hold a considerable share of the market during the forecast period, due to the increasing frequency of paroxysmal atrial fibrillation in elderly patients and the high preference for drugs over surgical methods during treatment.

  • Based on technology, the market is fragmented into radiofrequency, laser, cryotherapy, and others. The radiofrequency segment holds a key share of the market. Factors such as an increase in arrhythmias that can’t be controlled by medication are driving the demand for radiofrequency treatment.

  • Based on end-user, the market is segmented into hospitals, specialty clinics, and others. The hospital segment is anticipated to expand at a significant CAGR during the forecast period, as the radiofrequency, laser, and cryotherapy techniques are primarily performed in hospitals by specialized doctors.

  • Based on regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.  North America accounted for a significant share of the market in 2021, due to the growing geriatric population and rising prevalence of cardiovascular diseases. The market in Europe is anticipated to expand at a significant CAGR during the forecast period, due to the rising expenditure on healthcare infrastructure in Europe, with a key focus on paroxysmal atrial fibrillation treatment.

Report Scope

Report Metric

Details

Market Value in 2021

US$ 4,822.5 Million

Market Growth Rate (from 2021 to 2030)

8.8%

Historical Data

2015 & 2020

Base Year

2021

Forecast Period

2022 – 2030

Units Considered

Value (US$ Million)

Market Segments

By Treatment Type, By Technology, By End-user, and By Region

Key Companies Profiled

ATRICURE, INC., Abbott, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CardioFocus, Johnson & Johnson Services, Inc., Medtronic, Rising Pharma Holdings, Inc., Sanofi, and Siemens Medical Solutions USA, Inc.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience

  • Supply-side: Vendor, Manufacturer, Distributors, Supplier, Retailer.

  • Regulatory Side: Concerned government authorities, and other approved regulatory bodies.